742091-98-1Relevant academic research and scientific papers
MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF
-
Paragraph 0104; 0105; 0106, (2018/05/27)
The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.
METHOD OF TREATING CANCER BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS
-
, (2017/12/29)
The invention described herein relates to methods for treating a cancer using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker. More particularly, the invention described herein relates to methods for treating a cancer using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker to target myeloid-derived suppressor cells.
Design and synthesis of releasable folate-drug conjugates using a novel heterobifunctional disulfide-containing linker
Satyam, Apparao
supporting information; experimental part, p. 3196 - 3199 (2009/04/11)
Cellular uptake of vitamin folic acid occurs via folate-receptor mediated endocytosis. Many types of cancer cells express high levels of folate receptors as they need continuous supply of this vitamin for their proliferation. With an objective to use foli
BIVALENT LINKERS AND CONJUGATES THEREOF
-
Page/Page column 20, (2008/06/13)
Bivalent linkers derived from compounds of formulae (V), (VI) and (VII), where X1 and X2 are leaving groups and the other variables are as defined in the claims, to be included in or for preparing vitamin, drug, diagnostic agent, and
